Policy ForumHIV/AIDS

ARVs as HIV Prevention: A Tough Road to Wide Impact

Science  23 Dec 2011:
Vol. 334, Issue 6063, pp. 1645-1646
DOI: 10.1126/science.1212353

You are currently viewing the summary.

View Full Text

Via your Institution

Log in through your institution

Log in through your institution


Summary

Compelling new evidence showing that oral antiretroviral drugs (ARVs) can prevent heterosexual HIV transmission has recently burst upon us. The HPTN 052 randomized study confirmed earlier observational data that, if the HIV-positive partner in a discordant couple took ARVs, transmission to the HIV-negative partner was virtually eliminated, at least for more than 2 years (1). Two randomized studies found that taking ARVs by the HIV-negative partner in a discordant couple (preexposure prophylaxis or PrEP) also reduced transmission substantially (2). These results have ignited enthusiasm for ARVs as a breakthrough for HIV prevention. Indeed, Joint United Nations Programme on HIV/AIDS (UNAIDS) Executive Director Michel Sidebe has described it as “game changing” (3).

  • * The views expressed are not necessarily those of U.S. Agency for International Development.

Related Content